Buprenorphine for Drug Addition Treatemnt
Buprenorphine: This is a relatively new and important treatment medication. NIDA-supported basic and clinical research led to the development of buprenorphine (Subutex or, in combination with naloxone, Suboxone), and demonstrated it to be a safe and acceptable drug rehab. While these products were being developed in concert with industry partners, Congress passed the drug rehab Treatment Act (DATA 2000), permitting qualified physicians to write prescriptions narcotic medications (Schedules III to V) for the treatment of opioid addiction. This legislation created a major paradigm shift by allowing access to opiate treatment in a medical setting rather than limiting it to specialized %R_KEYWORD% treatment clinics. To date, nearly 10,000 physicians have taken the training needed to prescribe these two medications, and nearly 7,000 have registered as potential providers.
Residential Treatment Programs
Some Residential drug rehab treatment programs can also be very effective, especially for those with more severe problems. For example, %R_KEYWORD% therapeutic communities (TCs) are highly structured programs in which patients remain at a residence, typically for 6 to 12 months. Patients in TCs may include those with relatively long histories of drug addiction, involvement in serious criminal activities, and seriously impaired social functioning. TCs are now also being designed to accommodate the needs of women who are pregnant or have children. The focus of the TC is on the re-socialization of the patient to a drug-free, crime-free lifestyle.
help heroin addicts